The time is now to align on a shared plan of action as a country to achieve diversity, equity, inclusion, and access in US ...

As our nation ages, with the need to address more mental health and loneliness challenges than ever, it is time to design new ...

On September 30, a federal district judge in Florida held for the first time that lawsuits initiated by whistleblowers under the False Claims Act are unconstitutional, dismissing a Medicare fraud case ...

Health Affairs' Editor-in-Chief Alan Weil interviews Janice Jhang of Harvard University about her recent paper that explores how regulatory and market forces are driving adoption of biosimilars.

Regulation of health system consolidation should take into account all aspects of the market for health care goods and ...

Before the COVID-19 pandemic, for-profit nursing homes’ revenue generally covered their costs, whereas not-for-profit nursing homes often needed donations and other nonpatient revenue to cover ...

The NIH’s current system for funding scientific research perpetuates health disparities by privileging established, well-resourced institutions and reinforcing an individual-level focus on disease ...

Biosimilars present a key opportunity to contain the growing cost of biologic drug spending and to make essential medications more affordable. However, the lackluster performance of the US biosimilar ...

The sweeping relief sought by plaintiffs could erode protections for consumers against unanticipated financial liabilities ...

Project 2025 has gained national attention in recent months for its plan to fundamentally reshape the role of government and the power of the executive branch to allow more favorable conditions ...

In a frequently cited June 2022 article in Health Affairs, Sherry A. Glied, Dahlia K. Remler, and Mikaela Springsteen argue that health savings accounts (HSAs) are no longer functioning as ...